• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 19th May 2016

OHE at ISPOR May 2016: Meet the Team

ISPOR’s 21st Annual International Meeting is scheduled for 20-25th May 2016 in Washington DC. Several members of the OHE team will be attending and disseminating important research. ISPOR’s 21st Annual International Meeting will be held 20-25th May 2016 in Washington…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

ISPOR’s 21st Annual International Meeting is scheduled for 20-25th May 2016 in Washington DC. Several members of the OHE team will be attending and disseminating important research.

ISPOR’s 21st Annual International Meeting will be held 20-25th May 2016 in Washington DC. Several members of the OHE team will be attending and disseminating important research. We would welcome the opportunity to meet with you to discuss our research; individual contact details can be found through our Meet the Team webpage.

You will also find members of the OHE team presenting at the following sessions:

Short course: Risk Sharing / Performance-Based Arrangements for Drugs and Other Medical Products

OHE Authors: Adrian Towse

Time and date: Saturday 21st May, 8:00am

Summary: There is significant and growing interest among both the payers and producers of medical products for arrangements that involve a “pay-for-performance” or “risk-sharing” element. These payment schemes involve a plan by which the performance of the product is tracked in a defined patient population over a specified period of time and the level of reimbursement is tied by formula to the outcomes achieved. Although these agreements have an intrinsic appeal, there can be substantial barriers to their implementation. Issues surrounding theory and practice, including incentives and barriers, will be analysed along with several examples of performance-based schemes from Europe, the United States, and Australia.

Short course: Using Multi-Criteria Decision Analysis in Health Care Decision Making: Approaches & Applications

OHE Authors: Martina Garau and Nancy Devlin.  

Time and date: Sunday 22nd May, 1:00pm.

Summary: The aims of the course are:

  • To outline the steps involved in implementing multi-criteria decision analysis (MCDA)
  • To explain some of the methodological choices and practical issues when implementing these steps
  • To demonstrate how MCDA is being used for health technology assessment (HTA), the challenges and the opportunities this poses, and possible solutions to these challenges.

Research Podium Presentation: Health Care Expenditure Series: Multi-Indication Pricing: Pros, Cons and its Applicability to the UK

OHE Authors: Jorge Mestre-Ferrandiz  and Adrian Towse

Time and date: Monday 23rd May, 3:45pm.

Summary: Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. This presentation will explore the feasibility of implementing MIP in the UK.

Workshop: Risk-Sharing Agreements for Manufacturers and Commercial Payers in the United States: How Can Theory Help Practice?

OHE Authors: Adrian Towse

Time and date: Monday 23rd May, 5:00pm – 6:00pm.

Summary: Previous research has documented the limited use of risk-sharing agreements (RSAs) in the U.S. commercial sector for both medicines and devices. Research has also identified numerous practical barriers, including the costs of reaching an agreement and the lack of adequate data infrastructure. From a theoretical perspective, these agreements attempt to address the key uncertainties by (1) collecting real-world data post-launch, and (2) sharing risk by adjusting post-launch reimbursement. This problem has been characterized from a variety of theoretical perspectives–from value of information theory to real option theory to Bayes theorem. This workshop explores the utility of these approaches to help parties to the agreement construct an arrangement appropriate to the source of the uncertainty and their risk preferences. 

Issue Panel: Multi-Indication Pricing: Do We Want It? Can We Operationalize It?

OHE’s Adrian Towse will moderate this issue panel.

Time and date: Tuesday 24th May, 11:00am – 12:00pm.

Summary: Economic assessment will often describe different incremental health gains for different uses of a drug. This may be in different indications for the same drug or in different groups of patients (e.g. high risk / low risk) for the same indication. However, most health care reimbursement models use a single reimbursement price regardless across all indications. Multi-indication drug pricing represents a potential shift in drug reimbursement practice and has been debated in policy forums in both Europe and the US. Adrian Towse will moderate and briefly present a European perspective including opinions from an OHE supported stakeholder forum. Bill Dreitlein will provide US perspective including opinions from an ICER supported stakeholder forum. Ansgar Hebborn will provide a manufacturer’s point of view. Sean Karbowicz will provide a US payer’s perspective.

Poster: Value of Transferability and Efficiency in HTA

OHE Authors: Bernarda Zamora, Grace Marsden and Adrian Towse

Time and date: Monday 23rd May, 3:45pm – 7:45pm. Poster Author Discussion Hour: 6:45pm – 7:45pm

Summary: Existing literature on transferability advises that multinational trials should report country-specific cost-effectiveness results, yet typically these country specific results are only used to assess the between-location variability. 

We use value of information (VOI) analysis (assuming a normal distribution) to show that country specific results can be used to calculate the value of transferability (transfer from the wide trial to the country of interest) in terms of the Expected Value of Sample Information (EVSI).

Poster: The Distribution of the EQ-5D-5L Index in Patients Populations

OHE Authors: Yan Feng, Nancy Devlin and Bernarda Zamora.

Time and date: Monday 23rd May, 3:45pm – 7:45pm. Poster Author Discussion Hour: 6:45pm – 7:45pm

Summary: The distribution of the EQ-5D-3L index in patient populations often shows two distinct groups, arising both from the distribution of ill health and how the EQ-5D-3L index is constructed. This study aims to explore (a) whether or not the EQ-5D-5L index distribution also demonstrates clustering; (b) the extent to which clustering of EQ-5D-5L profile data is a driver of any observed clustering of the EQ-5D-5L index; and the extent to which clusters are a product of the value sets used to estimate the EQ-5D-5L index; and (c) to highlight the implications of our results for statistical analysis of EQ-5D-5L index data.

Poster: An Exploration of the Cultural Differences between the General Populations of Europe and Japan in Self-Reporting and Valuation of Pain

OHE Authors: Yan Feng and Nancy Devlin

Time and date: Tuesday 24th May, 3:45pm – 7:45pm. Poster Author Discussion Hour: 6:45pm – 7:45pm

Summary: This research investigates whether there are differences in the self-reporting and valuation of pain/discomfort between three countries (England/UK, Japan and Spain) on EQ-5D. Existing data sets were used to explore differences in responses to the EQ-5D descriptive system between Japan (3L and 5L), the UK (3L), England (5L) and Spain (5L), particularly on the dimension of pain/discomfort.

Poster: Health Technology Assessment of Complementary Diagnostics: Issues, Options, and Opportunities

OHE Authors: Jorge Mestre-Ferrandiz and Bernarda Zamora

Time and date: Wednesday 25th May, 8:30am – 1:30pm. Poster Author Discussion Hour: 12:30pm – 1:30pm

Summary: The poster is based on a White Paper which looks at the new concept of “complementary diagnostics”, defining tests using biomarkers for the purposes of risk assessment, diagnosis, prognosis, monitoring, and guiding therapeutic decisions. The White Paper presents a more comprehensive framework for considering the value contribution of complementary diagnostics. Going beyond the usual focus on health gain and cost savings, the framework highlights the value to the patient of having greater certainty of treatment benefit. The Paper also identifies several other sources of value related to information, including real option value, the value of hope, insurance value and scientific spillovers.

Poster: Data Governance for Real-World Evidence: Cross-Country Differences and Recommendations for a Governance Framework

OHE Authors: Jorge Mestre-Ferrandiz and Amanda Cole

Time and date: Wednesday 25th May, 8:30am – 1:30pm. Poster Author Discussion Hour: 12:30pm – 1:30pm

Summary: Real-world data (RWD) becomes real-world evidence (RWE) – what is really of value to stakeholders – after a series of activities which facilitate the transformation of raw data into analysis and results. Appropriate and facilitative governance arrangements for RWE are imperative to facilitate evidence collection that meets the demands of regulators and HTA bodies, and to make the most of health care information and the role it can play in improving patient care.

Poster: Does Society Wish to Place Greater Weight on a Unit of Health Gain for End-of-Life Patients than on that for Other Types of Patients?

OHE Authors: Koonal Shah

Time and date: Wednesday 25th May, 8:30am – 1:30pm. Poster Author Discussion Hour: 12:30pm – 1:30pm

Summary: This poster provides a review of the published literature on society’s preferences regarding the prioritisation of end of life treatments. Seventeen empirical studies are included in the review. Preliminary results were featured in a previous OHE blog.

Poster: Important Aspects of (Full) Health Not Captured by EQ-5D

OHE Authors: Koonal Shah

Time and date: Wednesday 25th May, 8:30am – 1:30pm. Poster Author Discussion Hour: 12:30pm – 1:30pm

Summary: This poster presents the methods and findings of a study seeking to identify important aspects of health that are not captured by the five EQ-5D dimensions. The study draws on the views of 456 members of the UK general public.

For further information on any of these presentations please contact the OHE authors via our Meet the Team webpage.

  • EQ-5D and PROMs
  • Events

Related News

IRA-course-graphic-for-website-news-FINAL-1
  • News
  • May 2023

New free educational program launched – Explaining the U.S. Inflation Reduction Act

Read more
MicrosoftTeams-image-6_0
  • News
  • June 2022

OHE’s 60th Anniversary Party – Celebrating Our Achievements and Looking Forward

Read more
  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!